Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "THOR Study - Erdafitinib vs. Pembrolizumab in Pretreated Patients With Advanced/Metastatic Urothelial Cancer With Select FGFR Alterations"

174 views
November 3, 2023
Comments 0
Login to view comments. Click here to Login